X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2231) 2231
humans (2185) 2185
bortezomib (1401) 1401
male (1312) 1312
female (1156) 1156
pyrazines - therapeutic use (1109) 1109
middle aged (1068) 1068
pyrazines - adverse effects (1059) 1059
pyrazines - administration & dosage (918) 918
aged (904) 904
multiple myeloma - drug therapy (770) 770
adult (735) 735
oncology (706) 706
boronic acids - adverse effects (673) 673
boronic acids - administration & dosage (662) 662
boronic acids - therapeutic use (619) 619
treatment outcome (591) 591
hematology (524) 524
multiple myeloma (511) 511
pyrazines - pharmacology (478) 478
antineoplastic combined chemotherapy protocols - therapeutic use (470) 470
animals (451) 451
antineoplastic agents - therapeutic use (432) 432
sitagliptin phosphate (401) 401
antineoplastic agents - adverse effects (399) 399
diabetes mellitus, type 2 - drug therapy (339) 339
antineoplastic combined chemotherapy protocols - adverse effects (293) 293
therapy (292) 292
aged, 80 and over (290) 290
pharmacology & pharmacy (289) 289
care and treatment (286) 286
triazoles - therapeutic use (265) 265
cancer (251) 251
dexamethasone - administration & dosage (238) 238
dexamethasone (230) 230
drug therapy, combination (229) 229
hypoglycemic agents - therapeutic use (228) 228
dose-response relationship, drug (226) 226
thalidomide (214) 214
research (211) 211
thalidomide - analogs & derivatives (210) 210
chemotherapy (209) 209
drug therapy (209) 209
abridged index medicus (201) 201
boronic acids - pharmacology (201) 201
antineoplastic agents - administration & dosage (199) 199
triazoles - adverse effects (197) 197
mice (196) 196
stem-cell transplantation (195) 195
thalidomide - administration & dosage (189) 189
medicine & public health (186) 186
multiple-myeloma (184) 184
drug administration schedule (179) 179
endocrinology & metabolism (179) 179
recurrence (176) 176
sitagliptin (175) 175
type 2 diabetes (175) 175
clinical trials as topic (174) 174
protease inhibitors - therapeutic use (171) 171
apoptosis (169) 169
trial (168) 168
proteasome inhibitors (165) 165
hypoglycemic agents - adverse effects (161) 161
hematology, oncology and palliative medicine (154) 154
analysis (153) 153
multiple myeloma - pathology (153) 153
thalidomide - therapeutic use (151) 151
dosage and administration (147) 147
transplantation (146) 146
diabetes (145) 145
rats (142) 142
retrospective studies (140) 140
proteasome inhibitor bortezomib (138) 138
disease-free survival (137) 137
pyrazines - pharmacokinetics (136) 136
clinical trials (135) 135
dipeptidyl-peptidase iv inhibitors - therapeutic use (134) 134
antineoplastic agents - pharmacology (132) 132
article (131) 131
multiple myeloma - mortality (129) 129
multiple myeloma - therapy (127) 127
time factors (127) 127
medicine, general & internal (126) 126
triazoles - administration & dosage (126) 126
double-blind method (125) 125
lenalidomide (125) 125
survival (125) 125
combination (124) 124
efficacy (123) 123
risk factors (123) 123
double-blind (120) 120
follow-up studies (120) 120
prognosis (119) 119
peripheral neuropathy (118) 118
multiple myeloma - complications (117) 117
hypoglycemic agents - administration & dosage (116) 116
protease inhibitors - adverse effects (116) 116
thalidomide - adverse effects (116) 116
peripheral nervous system diseases - chemically induced (115) 115
antineoplastic combined chemotherapy protocols - administration & dosage (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2276) 2276
Japanese (41) 41
Chinese (32) 32
German (26) 26
French (20) 20
Italian (11) 11
Spanish (11) 11
Swedish (6) 6
Russian (5) 5
Polish (4) 4
Czech (3) 3
Danish (3) 3
Hebrew (2) 2
Norwegian (2) 2
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Blood, ISSN 0006-4971, 05/2016, Volume 127, Issue 20, pp. 2411 - 2415
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 22, pp. 5752 - 5758
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 448 - 455
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 2/2014, Volume 30, Issue 2, pp. 163 - 175
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4621 - 4629
Journal Article
Leukemia, ISSN 0887-6924, 12/2008, Volume 22, Issue 12, pp. 2247 - 2256
This phase 2 study aimed to determine the efficacy and safety of the combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT)... 
SURVIVAL | multiple myeloma | REFRACTORY MULTIPLE-MYELOMA | RESORPTION | melphalan | angiogenesis | PROTEASOME INHIBITOR PS-341 | MARKERS | ZOLEDRONIC ACID | bone metabolism | CHEMOTHERAPEUTIC-AGENTS | SERUM CONCENTRATIONS | thalidomide | ONCOLOGY | RECEPTOR ACTIVATOR | bortezomib | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Neovascularization, Physiologic - drug effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bone Remodeling - drug effects | Bone and Bones - drug effects | Antineoplastic Agents, Hormonal - adverse effects | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Bone and Bones - metabolism | Aged, 80 and over | Adult | Female | Boronic Acids - administration & dosage | Immunosuppressive Agents - administration & dosage | Multiple Myeloma - physiopathology | Biomarkers - metabolism | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Cytokines - metabolism | Antineoplastic Agents, Hormonal - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Multiple Myeloma - metabolism | Melphalan - administration & dosage | Pyrazines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Antineoplastic Agents, Alkylating - adverse effects | Antimitotic agents | Multiple myeloma | Physiological aspects | Genetic aspects | Dosage and administration | Drug therapy, Combination | Neovascularization | Research | Drug therapy | Antineoplastic agents | Health aspects | Index Medicus
Journal Article